Clinical trial
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN…
NCT00411385 · Human Genome Sciences Inc., Industry · Completed
Key facts
| NCT number | NCT00411385 |
|---|---|
| Title | Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 |
| Official title | Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3. |
| Lead sponsor | Human Genome Sciences Inc., Industry |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin |
| Enrollment | 933 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Dec 14, 2006 |
| Last update posted | Aug 8, 2013 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, France, Germany, India, Israel, Malaysia, Mexico, Poland and 9 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: